TITLE

Wie wirksam ist Rituximab bei der rheumatoiden Arthritis?

AUTHOR(S)
Schmidt, W. A.; Schicke, B.; Krause, A.; Wernicke, D.
PUB. DATE
June 2010
SOURCE
Zeitschrift für Rheumatologie;Jun2010, Vol. 69 Issue 4, p349
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Does experience with rituximab treatment of rheumatoid arthritis (RA) in daily clinical practice confirm the results of controlled randomized studies? This is a retrospective data-analysis of the first 50 patients from one center with rituximab treatment for RA. The patients received at least one cycle of 2 rituximab infusions (1000 mg, respectively) within 2 weeks. Clinical assessment was performed 3–5 months after the first infusion. The patients were older (mean age, 59 years) as compared to previously published controlled studies. The DAS28 was lower (5.5). The mean prednisolone dose was high (13.4 mg/d). The rheumatoid factor was positive in 88% of patients. Only six patients would have fulfilled inclusion criteria for controlled studies such as prednisolone dose ≤10 mg/d, concomitant methotrexate treatment, previous TNF-inhibitor treatment, or absence of malignancy. Nevertheless, indications were compatible with recently published German Rheumatology Society recommendations on rituximab treatment. A total of 62% of patients achieved EULAR response, 20% good response and 10% remission. Response was greater in patients with concomitant methotrexate treatment (88% versus 53%). The results were independent of sex, presence of anti-CCP antibodies, ANA, and previous TNF-inhibitor treatment. Only three patients had pathologic infusion reactions at the first infusion and one patient at the second infusion. Rituximab proved to be effective, particularly when combined with methotrexate. Most patients differed considerably from those who had entered randomized controlled studies. Recently published German Rheumatology Society recommendations proved to be feasible as they reflect daily clinical practice. Results of controlled studies could be confirmed.
ACCESSION #
51523625

 

Related Articles

  • Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. Parker, Benjamin // Current Medical Literature: Rheumatology;2013, Vol. 32 Issue 2, p48 

    The author comments on the paper "Rituximab Dissociates the Tight Link Between Disease Activity and Joint Damage in Rheumatoid Arthritis Patients," by D. Aletaha and colleagues, published in "Annals of the Rheumatic Diseases." Results of the study showed that rituximab, in combination with...

  • Adalimumab for Rheumatoid Arthritis? Ebell, Mark; Kripke, Clarissa // American Family Physician;2/1/2006, Vol. 73 Issue 3, p435 

    Answers a question on the safety and effectiveness of adalimumab (Humira) for rheumatoid arthritis. Required dosage of adalimumab; Effectiveness of the combination of adalimumab with methotrexate; Indications for adalimumab.

  • Prevalence of dermatophytosis in patients with rheumatoid arthritis. Bicer, Ali; Tursen, Umit; Cimen, Ozlem Bolgen; Kaya, Tamer Irfan; Ozisik, Sacettin; Ikizoglu, Guliz; Erdogan, Canan // Rheumatology International;Jan2003, Vol. 23 Issue 1, p37 

    Objective. The prevalence of dermatophytic infections in rheumatoid arthritis is unknown. This study investigated the prevalence of dermatophytosis in patients with rheumatoid arthritis and the relationship between sulfasalazine, low-dose methotrexate and steroid therapy. Methods. We examined 53...

  • B Cell-Targeted Therapy for Rheumatoid Arthritis. Looney, R. John // Drugs;2006, Vol. 66 Issue 5, p625 

    Rheumatoid arthritis (RA) is a human systemic autoimmune disease with a prevalence of about 1%. Although an important role for B cells has been demonstrated in animal models of autoimmune, inflammatory arthritis, the importance of B cells in RA has been controversial for decades. The development...

  • REZUMATELE LUCRÄ‚RILOR PREZENTATE LA CONGRESUL ROMÂN DE REUMATOLOGIE.  // Romanian Journal of Rheumatology;2009, Vol. 18 Issue 3, p189 

    No abstract available.

  • CONDUTA NO DIAGNÓSTICO E TRATAMENTO DOS PACIENTES COM ARTRITE REUMATÓIDE NO BRASIL - RESPOSTAS DOS MÉDICOS A UM QUESTIONÁRIO DE AVALIAÇÃO. Ferraz, M. B.; de Soarez, P. C.; Riera, R.; Ciconelli, R. M. // Acta Reumatológica Portuguesa;jan-mar2009, Vol. 34 Issue 1, p44 

    Objectives: The aim of this study was to evaluate in relation to diagnosis and treatment for Rheumatoid Arthritis (RA) patients Brazilian population, and compare the management offered to patients who are followed up in the public and private sectors. Material and Methods: An electronic...

  • Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Fiehn, Christoph; Wunder, Andreas; Krienke, Stefan; Max, Regina; Ho, Anthony D.; Moehler, Thomas // Rheumatology International;Mar2005, Vol. 25 Issue 2, p108 

    Objectives: The aim of this study was to investigate whether methotrexate (MTX) has an antiangiogenic effect and whether this property plays a role in the control of rheumatoid arthritis (RA). Methods: A human placenta angiogenesis assay was used to examine the antiangiogenic effects of MTX in...

  • Monoarticular septic arthritis in a patient with juvenile rheumatoid arthritis under etanercept treatment. Lin, Kai-Cheng; Liang, Chi-Di; Yang, Kuender; Yu, Hong-Ren; Kuo, Ho-Chang // Rheumatology International;May2012, Vol. 32 Issue 5, p1383 

    A 7-year-old girl with polyarticular type juvenile rheumatoid arthritis (JRA) presented with acute onset of right hip pain with limited range of motion and fever within the past two days. She had received etanercept for more than one year. Percutaneous arthrocentesis was performed and showed a...

  • Editorials: Sulphasalazine in rheumatoid arthritis: an old drug revived. Neumann, V. C.; Grindulis, K. A. // Journal of the Royal Society of Medicine;Mar1984, Vol. 77 Issue 3, p169 

    The article discusses the benefits of sulphasalazine in treating rheumatoid arthritis. Sulphasalazine is an old drug which is a compound of sulphapyridine and 5-aminosalicylic acid linked by an azo bond. The benefits of salicylates in rheumatoid arthritis have an excellent effect on the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics